PUBLISHER: The Business Research Company | PRODUCT CODE: 1678162
PUBLISHER: The Business Research Company | PRODUCT CODE: 1678162
Non-alcoholic steatohepatitis (NASH) represents an advanced stage of fatty liver disease, distinguished by inflammation of the liver, and has the potential to progress to cirrhosis and liver failure.
Non-alcoholic steatohepatitis (NASH) is classified into solid and liquid forms. Solid variants are predominantly produced in crystalline forms, sold in tablet formats for oral consumption, owing to their superior purity and durability. Products in this category, such as vitamin E, pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, and others, target various health conditions including hypertension, heart disease, high blood lipid, type 2 diabetes, and obesity. These products are distributed through hospital pharmacies, retail pharmacies, and online providers, encompassing both oral and parenteral applications.
The non-alcoholic steatohepatitis (NASH) market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis (NASH) market statistics, including non-alcoholic steatohepatitis (NASH) industry global market size, regional shares, competitors with non-alcoholic steatohepatitis (NASH) market share, detailed non-alcoholic steatohepatitis (NASH) market segments, market trends, and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis (NASH) industry. This non-alcoholic steatohepatitis (NASH) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The non-alcoholic steatohepatitis (NASH) market size has grown exponentially in recent years. It will grow from $4.5 billion in 2024 to $6.13 billion in 2025 at a compound annual growth rate (CAGR) of 36.1%. The growth in the historic period can be attributed to rising prevalence of NASH, obesity epidemic, growing awareness and diagnoses, shift in lifestyle and dietary patterns, healthcare infrastructure development.
The non-alcoholic steatohepatitis (NASH) market size is expected to see exponential growth in the next few years. It will grow to $19.07 billion in 2029 at a compound annual growth rate (CAGR) of 32.8%. The growth in the forecast period can be attributed to advancements in NASH drug development, increasing NASH screening initiatives, rising healthcare expenditure, collaborative research efforts, government support and regulations. Major trends in the forecast period include focus on lifestyle interventions and patient education, increased collaboration in clinical research, regulatory advancements and pathway designations, integration of artificial intelligence in diagnosis and monitoring.
The increasing prevalence of obesity is driving the demand for the non-alcoholic steatohepatitis (NASH) market. Obesity is characterized by an abnormal or excessive accumulation of fat that poses significant health risks, as well as a body weight exceeding what is considered healthy for a person of a specific height. With the growing incidence of non-alcoholic fatty liver disease linked to the obesity epidemic, NASH is projected to become one of the leading causes of severe liver disease in the coming decades, heightening the demand for NASH treatments and related medications. For example, in March 2024, the World Health Organization (WHO), a UK-based international public health organization, reported that in 2022, approximately 2.5 billion adults aged 18 and older were classified as overweight, with 890 million of them living with obesity. Thus, the rise in obesity cases is expected to drive the growth of the non-alcoholic steatohepatitis (NASH) market.
The rising demographic of the geriatric population is a key driver fueling the demand for the non-alcoholic steatohepatitis (NASH) market. The geriatric population, representing individuals aged 65 and older, exhibits specific healthcare needs associated with aging. The ongoing development and advancements in treatments within the NASH market play a crucial role in enhancing overall health outcomes for the elderly, addressing a prevalent liver-related condition prevalent in aging individuals. As indicated by the World Health Organization in October 2022, the global elderly population is anticipated to witness a significant increase, with 1 in 6 individuals being 60 or older by 2030 and an estimated 2.1 billion elderly people by 2050. This demographic shift underscores the imperative role of the increasing geriatric population in driving the growth of the Non-Alcoholic Steatohepatitis (NASH) market.
Major companies in the non-alcoholic steatohepatitis (NASH) market are focusing on the development of thyroid hormone receptor-beta (THR-beta) agonists to improve liver metabolism, decrease liver fat accumulation, and enhance liver function. THR-beta agonists are compounds that specifically activate the thyroid hormone receptor-beta subtype, a crucial receptor involved in regulating metabolism, growth, and development. For instance, in March 2024, the U.S. Food and Drug Administration (FDA) approved Rezdiffra (resmetirom), the first treatment for adults with noncirrhotic NASH and moderate to advanced liver scarring (fibrosis). By selectively activating the THR-beta receptor, Rezdiffra aids in regulating lipid metabolism, resulting in a reduction of intrahepatic triglycerides and overall liver fat accumulation.
Prominent companies in the non-alcoholic steatohepatitis (NASH) market are actively engaged in the development of innovative products, exemplified by a focus on a thyroid hormone receptor (THR)-B selective agonist. This innovative therapeutic approach is designed to target fundamental underlying causes of non-alcoholic steatohepatitis. The thyroid hormone receptor, a pivotal protein regulating gene expression upon binding with thyroid hormones, plays a crucial role in various physiological processes. A case in point is Madrigal Pharmaceuticals, Inc., a US-based clinical-stage biopharmaceutical company, which completed the submission of a New Drug Application in July 2023, seeking accelerated approval for Resmetirom in the treatment of NASH with liver fibrosis. Resmetirom, offering once-daily oral therapy and liver-directed action, specifically targets hepatic steatosis, inflammation, and hepatocellular injury associated with NASH and liver fibrosis. Notably designated as a Breakthrough Therapy by the FDA, and supported by a comprehensive clinical development program, including Phase 3 trials, Resmetirom showcases significant potential to address unmet medical needs. This advancement positions it as a promising addition to the evolving treatment landscape for NASH with liver fibrosis.
In July 2022, Advanz Pharma Corp. Limited, a prominent UK-based pharmaceutical company, successfully acquired Intercept Pharmaceuticals Inc for an undisclosed sum. This strategic acquisition is designed to solidify Advanz Pharma's position in the rare disease treatment sector, specifically through the addition of the ex-U.S. rights to Ocaliva (obeticholic acid), an orphan medicine used for treating primary biliary cholangitis (PBC). Intercept Pharmaceuticals Inc., a distinguished U.S.-based biopharmaceutical company specializing in innovative therapies for progressive non-viral liver disorders, aligns well with Advanz Pharma's strategic goals in expanding its pharmaceutical portfolio.
Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the non-alcoholic steatohepatitis (nash) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The non-alcoholic steatohepatitis (NASH) market consists of sales of drugs that are used for the treatment of non-alcoholic fatty liver diseases. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on non-alcoholic steatohepatitis (nash) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for non-alcoholic steatohepatitis (nash) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-alcoholic steatohepatitis (nash) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.